<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161821</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 1121</org_study_id>
    <secondary_id>11-1924</secondary_id>
    <nct_id>NCT03161821</nct_id>
  </id_info>
  <brief_title>Circulating Tumor Cells in Solid Tumors</brief_title>
  <official_title>Quantification and Characterization of Circulating Tumor Cells in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify circulating tumor cells in patients with solid&#xD;
      tumors. Quantify and characterize these cells, collect patient information in regards to the&#xD;
      patient's cancer. Develop a database and a sample repository where future analysis could be&#xD;
      done.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this correlative study is to create a prospective database documenting&#xD;
      the quantity and characterization of circulating tumor cells (CTCs) in solid tumor patients&#xD;
      as identified by a various laboratory techniques and analyses. The investigators are&#xD;
      developing this resource to provide data to achieve the following objectives: 1) correlate&#xD;
      CTCs with known prognostic factors, 2) correlate CTCs with burden of disease, 3) evaluate the&#xD;
      ability of CTCs to be used in the surveillance of disease recurrence, and 4) evaluate CTCs&#xD;
      ability to be used as a biomarker for treatment response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 9, 2011</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Documentation of the Quality of CTCs from Patients with Solid Tumors</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Enumeration of participants' circulating solid tumor cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Documentation of the Characterization of CTCs from Patients with Solid Tumors</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Characterization of participants' circulating solid tumor cells</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cancerous solid tumors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years of age&#xD;
&#xD;
          -  Biopsy proven solid tumor malignancy&#xD;
&#xD;
          -  Seen at UNC Chapel Hill Hospital and Health Care System&#xD;
&#xD;
          -  Consents to abstraction of their medical records&#xD;
&#xD;
          -  Signed an institutional review board (IRB)-approved informed consent document for this&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
&#xD;
          -  Dementia, altered mental status, incarceration or any psychiatric condition that would&#xD;
             prohibit the understanding or rendering of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaorav P Gupta, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiation Oncology Clinic - UNC Cancer Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://unclineberger.org/patientcare/clinical-trials/clinical-trials</url>
    <description>UNC Lineberger Comprehensive Cancer Center Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

